http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-108261413-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4174 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4174 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-14 |
| filingDate | 2016-12-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2020-05-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2020-05-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-108261413-B |
| titleOfInvention | Application of IMB-301 in the preparation of antiviral drugs |
| abstract | The present invention relates to the application of compound IMB-301 in the preparation of antiviral drugs with hA3G as a target. Disclosed is an antiviral active compound targeting hA3G, which is obtained through virtual screening. The biological activity shows that IMB-301 can specifically inhibit Vif from degrading hA3G by inhibiting the binding of Vif to hA3G; and IMB-301 upregulates intracellular hA3G levels effectively inhibit the replication of viruses such as HIV, i.e. IMB‑301 is dependent on hA3G for virus inhibition. The active compound in the present invention selects hA3G as the target, which solves the drug resistance problem caused by the high mutation of the virus, and has no cross-drug resistance with the antiviral drugs currently used in clinical practice. |
| priorityDate | 2016-12-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 90.